|Bid||80.00 x 4000|
|Ask||0.00 x 1800|
|Day's Range||114.51 - 115.78|
|52 Week Range||80.08 - 124.79|
|Beta (3Y Monthly)||1.41|
|PE Ratio (TTM)||31.40|
|Forward Dividend & Yield||2.16 (1.86%)|
|1y Target Est||N/A|
With 5G wireless mobile phones on the way, the time has come to buy shares of the key radio component vendors, according to BofA Global Research.
The Cambridge Dictionary’s definition of an expert is a “person with a high level of knowledge or skill relating to a particular subject or activity.”Apply this to the investing world, and how do we see this in action? We pull out TipRanks’ Top Wall Street Firms and notice who sits at the top of the heap.Occupying the throne right now is renowned investment bank RBC Capital, which means that among the company’s employees there are seasoned pros with a proven track record for success. Utilizing the TipRanks Stock Screener tool, we’ve found three stocks receiving Strong Buy ratings from most analysts in general, and endorsed by RBC in particular. Let’s take a closer look: Ovid Therapeutics (OVID)Ovid Therapeutics shares are on a tear. The stock price of this neurological medicines firm has raced ahead 66% this year, leaving the Nasdaq Biotechnology ETF (IBB) in its dust. But would you believe it has even further to run? Would you believe it could go up another 200%? RBC analyst Brian Abrahams does. In his latest research note, Abrahams reiterated an Outperform rating on OVID, along with a price target of $12.00 (To watch Abraham’s track record, click here)The drug maker has several therapies in the pipeline. Leading programs in development right now are OV101, which focuses on a potential treatment for Angelman syndrome and Fragile X syndrome, two neurodevelopmental disorders caused by genetic mutations, and OV935, a program focused on developing potential therapies for people living with rare epilepsies.Top-line data from a Phase 3 NEPTUNE trial of OV101 in Angelman's Syndrome should be released in mid-2020, and Abrahams thinks there is a very reasonable chance of success. While acknowledging some risk given disease heterogeneity, unclear dose dependence, and inconsistent subdomain effects in ph.II, the 5-star analyst noted, “We believe clinical and preclinical data for the company's lead candidate OV101, an extrasynaptic GABAA receptor agonist, are in totality supportive of the drug's activity in Angelman Syndrome, and believe the stock price currently underappreciates the likelihood the drug succeeds in improving clinical symptoms of the disease in ph.III. Given the high unmet need in this population, we believe FDA will be permissive -- highlighted by the Agency's endorsement of the pivotal trial design -- and if approved, should enable good uptake and pricing power.”Other analysts are even more optimistic. Indeed, the average price target on Wall Street is $13.50 -- implying nearly 240% upside. And over the last three months, no one on the Street has assigned Ovid shares anything less than a "buy" rating. (See Ovid stock analysis on TipRanks)Anaplan (PLAN)This year has seen a number of car crash IPO’s, as several over valued startups got on the receiving end of a harsh reality check following public listings. One to avoid such a fate, is cloud computing ‘connected planning’ platform, Anaplan.The company’s name derives from the combination of analysis and planning, which makes sense to us, as it makes software that connects people in a shared environment to business data in order to make better-informed plans and decisions.Anaplan impressed Wall Street with its latest F3Q20 earnings report. The company handily beat expectations on several key metrics, including top-line, billings, and margins. Additionally, this led to management significantly boosting its FY20 guidance.RBC’s Alex Zukin believes that a ‘large addressable market’ can serve as a catalyst for Anaplan’s growth, noting, “Anaplan indicates that the Planning market is a $21B+ opportunity (based on IDC forecasts). We believe customers are paying legacy vendors billions of dollars today and there is potential for spend significantly above that if greenfield, excel-based business processes meaningfully start to convert to Planning vendors.”Anaplan’s growth potential has Zukin reiterating his Outperform rating, along with a price target of $70. PLAN is currently trading at $52.56, indicating gains of 33% might be in the cards should Zukin’s target materialize. (To watch Zukin’s track record, click here)What’s the Street’s plan for PLAN, then? The consensus is that the connected planning innovator is a Strong Buy, a rating achieved as a result of 9 "buy" and 3 "hold" ratings issued in the past 3 months. The average stock-price forecast of $63.33 implies upside potential of 20% from current levels. (See PLAN stock analysis on TipRanks)Analog Devices (ADI)Last and least, we come to semiconductor maker Analog Devices, which scored an "outperform" rating (i.e. "buy") from 5-star RBC analyst Mitch Steves.ADI stock is up nearly 38% in 2019 compared to the S&P 500, which has returned 24%. That’s impressive, but the big question for investors is whether the company (and its stock) can maintain the momentum. Steves suggests that if everything goes as planned, ADI will be a $136 stock in the next 12 months, implying about 18% return. (To watch Steves’ track record, click here)The company’s recent FQ4 numbers were mildly below Street expectations. Revenues of $1.44 billion slightly missed the Street’s estimate of $1.45 billion, while EPS of $1.19 came below the $1.22 estimate. FQ1 guidance also missed the Street’s targets.Steves commented, “We continue to believe that sentiment is still quite negative on the stock and remain positive as operating margin expansion should begin in Q2 and beyond [...] We remain positive on ADI and its suggestion of a recovery in Q2 is in line with our Analog view as well.” The analyst further added, “We are seeing positive trends within ADI’s communications business, as the company manages to sustain share gain and capture 5G opportunities. Being exposed to 5G radio content represents significant differentiation relative to the analog group, in our view.”The RBC expert is not alone in his take on ADI, as 11 Buys and 3 Holds from the analysts tracked by TipRanks over the last 3 months result in a Strong Buy consensus rating. The average price target stands at $125.57. (See ADI stock analysis on TipRanks)
The Norwood-based semiconductor company, which has more than $40 billion in market capitalization, is suing a chipmaker the company has worked with for years.
It's been a good week for Analog Devices, Inc. (NASDAQ:ADI) shareholders, because the company has just released its...
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]
Adjusted profits were $1.19 a share, lower than the company had told investors to expect, and below the consensus view among Wall Street analysts that earnings would be $1.22 a share.
Jon Najarian spoke on CNBC's "Fast Money Halftime Report," about unusually high options activity in Analog Devices, Inc. (NASDAQ: ADI ) and United States Natural Gas Fund, LP (NYSE: UNG ). Options ...
Chipmaker Analog Devices on Tuesday missed Wall Street's targets for its fiscal fourth quarter and guided lower for the current quarter. ADI stock wavered following the earnings report.
Analog Devices (ADI) delivered earnings and revenue surprises of -1.65% and -0.63%, respectively, for the quarter ended October 2019. Do the numbers hold clues to what lies ahead for the stock?
Analog Devices Inc. shares are down 3.5% in premarket trading Tuesday after the company saw earnings and revenue slip in its October quarter. The company reported fiscal fourth-quarter net income of $266.7 million, or 74 cents a share, down from $404.9 million, or $1.08 a share, in the year-earlier period. Adjusted earnings per share fell to $1.19 from $1.48. Analog Devices posted revenue of $1.44 billion, down from $1.54 billion a year earlier. Analysts surveyed by FactSet were expecting $1.45 billion. For the fiscal first quarter, Analog Devices expects revenue of $1.25 billion to $1.35 billion and adjusted earnings per share of 93 cents to $1.07. The stock has gained 32% so far this year, as the S&P 500 has risen 25%.
Analog Devices, Inc. (Nasdaq: ADI), a leading global high-performance analog technology company, today announced financial results for its fourth quarter and fiscal 2019, which ended November 2, 2019.
Investing.com - Analog Devices reported fourth quarter earnings that missed analysts' expectations on Tuesday and revenue that fell short of forecasts.
It’s a Thanksgiving-shortened week. Analog Devices, Dell Technologies, Best Buy, and Deere all report. Plus, data on consumer income and spending and business investment.
Analog Devices' (ADI) strength in end-markets served is likely to reflect on fiscal fourth-quarter 2019 results. However, softness in the consumer market and geopolitical uncertainty may have remained concerns.
On Wednesday morning, Benzinga Pro subscribers received two option alerts related to unusually large Analog Devices trades. At 9:36 a.m., a trader bought 1,817 Analog Devices put options with a $110 strike price expiring on Nov. 29 near the ask price at $2.80. At 9:46 a.m., a trader sold 825 Analog Devices put options with a $95 strike price expiring on Jan. 17, 2020 near the bid price at $1.076.
Analog Devices (ADI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Today we'll look at Analog Devices, Inc. (NASDAQ:ADI) and reflect on its potential as an investment. Specifically...
Local elections tend to draw less intensity and a smaller crowd than presidential and statewide contests, despite the ground-level impact of municipal officials. But this year’s elections have also attracted a super PAC with ties to Gov. Charlie Baker and donations from top Massachusetts executives.
Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of MaxLinear, Inc. New York, October 29, 2019 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of MaxLinear, Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.